|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat显示文摘AIM: To present the characteristics and the course of a series of anti- hepatitis B virus core antibody (HBc) antibody positive patients, who experienced hepatitis B virus (HBV) reactivation after immunosuppression. METHODS: We retrospectively evaluated in our tertiary centers the medical records of hepatitis B virus surface antigen (HBsAg) negative patients who suffered from HBV reactivation after chemotherapy or immunosuppression during a 3-year period (2009-2011). Accordingly, the clinical, laboratory and virological characteristics of 10 anti-HBc (+) anti-HBs (-)/HBsAg (-) and 4 anti-HBc (+)/antiHBs (+)/HBsAg (-) patients, who developed HBV reactivation after the initiation of chemotherapy or immunosuppressive treatment were analyzed. Quantitative determination of HBV DNA during reactivation was performed in all cases by a quantitative real time polymerase chain reaction kit (COBAS Taqman HBV Test; cut-off of detection: 6 IU/mL). RESULTS: Twelve out of 14 patients were males; median age 74.5 years. In 71.4% of them the primary diagnosis was hematologic malignancy; 78.6% had received rituximab (R) as part of the immunosuppressive regimen. The median time from last chemotherapy schedule till HBV reactivation for 10 out of 11 patients who received R was 3 (range 2-17) mo. Three patients (21.4%) deteriorated, manifesting ascites and hepatic encephalopathy and 2 (14.3%) of them died due to liver failure. CONCLUSION: HBsAg-negative anti-HBc antibody positive patients can develop HBV reactivation even 2 years after stopping immunosuppression, whereas prompt antiviral treatment on diagnosis of reactivation can be lifesaving. | Kalliopi Zachou Alexandros Sarantopoulos Nikolaos K Gatselis Themistoklis Vassiliadis Stella Gabeta Aggelos Stefos Asterios Saitis Panagiota Boura George N Dalekos | 2013 | World Journal of Hepatology2013，5，7： | 6 |
| 2 | 七氟烷、地氟烷或丙泊酚麻醉术后疼痛和镇痛药需求量的比较显示文摘背景全身麻醉药可产生伤害反应从而影响手术后疼痛,在一些手术后疼痛的研究中,均没有考虑全麻药对镇痛药需要量的影响,仅有最近一项研究显示丙泊酚麻醉的手术后镇痛效果比异氟烷麻醉好。方法前瞻性、随机、双盲研究,记录在七氰烷、地氟烷或丙泊酚麻醉下行腹式子宫切除术或子宫肌瘤切除手术患者手术后2、4、8、和24小时吗啡的需要量和疼痛评分(疼痛视觉模拟评分,VAS),手术中维持BIS35~45。同时记录患者送至麻醉监护室时的疼痛评分。结果3组患者手术后2、4、8或24小时,吗啡累积消耗量无差异(P=0.50)。手术后24小时内吗啡消耗量:七氟烷组28±13.8mg;地氟垸组25±11.7mg;丙泊酚组27±16.1mg。疼痛评分在患者转运至麻醉监护室即刻、手术后2、4、8和24小时,分别在静息及咳嗽状态下评估,显示3组间无差异(静息时P=0.40、0.39、0.50、0.47、0.06;咳嗽后P=0.67、0.45、0,22、0.26、0.29).结论手术后24小时吗啡消耗量和手术后疼痛情况在七氟烷、地氟烷或丙泊酚3组间差异无显著性。 | Argyro Fas s oulaki Aikaterini Melemeni Anteia Paraskeva Ioanna Siafaka Constantine Sarantopoulos 宋村笛(译) 李士通(校) | 2009 | 麻醉与镇痛2009，，6： | 2 |
| 3 | High levels of Bcell activating factor in patients with active chronic graft-versushost disease 显示文摘 | Sarantopoulos S Stevenson KE Kim HT | 2007 | Clin Cancer Res2007，13，： | 1 |
| 4 | Imaging the Bio-Distribution of fluorescent probes using muhispectral Epi-Illumination cryoslicing imaging 显示文摘 | Sarantopoulos A Themelis G Ntziachristos V | 2011 | Molecular Imaging and Biology2011，13，5： | 1 |
| 5 | High levels of B-cell activating factor in patients with active chronic graft-versushost disease显示文摘 | Sarantopoulos S Stevenson KE Kim HT | 2007 | Clin Cancer Res2007，13，： | 1 |
| 6 | Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant显示文摘 | Sankhala KK Pandya DM Sarantopoulos J | 2009 | Expert Opin Drug Metab Toxicol2009，5，12： | 1 |
| 7 | Qa-1 restriction of CD8^+ suppressor T cells显示文摘 | Sarantopoulos S Lu L Cantor H | 2004 | J Clin Invest2004，114，9： | 1 |
| 8 | Immunohistochemical characteristics of melanoma显示文摘 | Ohsie S J Sarantopoulos GP Cochran AJ | 2008 | J Cutan Pathol2008，35，5： | 1 |
| 9 | Immunohistochemical characteristics of melanoma 显示文摘 | Ohsie SJ Sarantopoulos GP Coehran AJ | 2008 | J Cutan Pathol2008，35，5： | 1 |
| 10 | The aualgesic effect of gabapentin and mexiletine after breast surgery for cancer 显示文摘 | Fassoulaki A Patris K Sarantopoulos C | 2002 | Anesth Analg2002，95，4： | 1 |
| 11 | Nuclear cholesterol content and nucleoside triphosphatase activity are altered in the JCR:LA-cp corpulent rat显示文摘 | Czubryt MP Russell JC Sarantopoulos J | 1996 | J Cell Biochem1996，63，： | 1 |
| 12 | Dynamic loading performance of fasciocutaneous flaps and implications for gait显示文摘 | Karakostas T Hsiang SM Sarantopoulos C | 2007 | Clin Biomech(Bristol Avon)2007，22，4： | 1 |
| 13 | The analgesic effect of gabapentin and mexiletine after breast surgery for cancer显示文摘 | Fassoulaki A Patris K Sarantopoulos C | 2002 | Anesth Analg2002，95，4： | 1 |
| 14 | Tesetaxel,a new oral taxane,in combination with capecitabine: a phase Ⅰ,dose-escalation study in patients with advanced solid tumors显示文摘 | Saif MW Sarantopoulos J Patnaik A | 2011 | Cancer Chemother Pharmcol2011，68，6： | 1 |
| 15 | Flumazenil reduces the dura- tion of thiopentone but not of propofol anaesthesia in humans 显示文摘 | Fassoulaki A Sarantopoulos C Papilas K | 1993 | Can J Anesth1993，40，1： | 1 |
| 16 | Qa-1 restriction of CD8+ suppressor T cells显示文摘 | Sarantopoulos S Lu L Cantor H | 2004 | J Clin Invest2004，114，9： | 1 |
| 17 | Effeetor CD4+ T cells, the cytokines they generate, and GVHD: some- thing old and something new显示文摘 | Coghill J M Sarantopoulos S Moran T P | 2011 | Blood2011，117，： | 1 |
| 18 | Phase I , pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor l 显示文摘 | Tolcher AW Sarantopoulos J Patnaik A | 1997 | J Clin Oncol1997，27，34： | 1 |
| 19 | Relative bio- availability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors 显示文摘 | Falchook GS Venkatakrishnan K Sarantopoulos J et aI | 2015 | Int J Clin Pharmacol Ther2015，53，7： | 1 |
| 20 | Phase Ⅰ study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies显示文摘 | Mita M Mita A Sarantopoulos J | 2009 | Cancer Chemother Pharmcol2009，64，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员